Sarepta Therapeutics, Inc. (SRPT) Files Form 4 Insider Selling : David T Howton Sells 9,304 Shares

Sarepta Therapeutics, Inc. (SRPT): David T Howton , SVP, General Counsel of Sarepta Therapeutics, Inc. sold 9,304 shares on Sep 19, 2016. The Insider selling transaction was reported by the company on Sep 21, 2016 to the Securities and Exchange Commission. The shares were sold at $50.00 per share for a total value of $465,200.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 16, 2016, Edward M. Md Kaye (SVP Interim CEO & CMO) sold 24,557 shares at $30.00 per share price.On Mar 16, 2016, M Kathleen Behrens (director) purchased 75,000 shares at $15.54 per share price.Also, On Mar 16, 2016, Ben Gil Price (director) purchased 4,500 shares at $16.70 per share price.On Mar 16, 2016, Richard Barry (director) purchased 75,000 shares at $15.66 per share price.

Sarepta Therapeutics Inc: On Tuesday, Sep 21, 2016 heightened volatility was witnessed in Sarepta Therapeutics Inc which led to swings in the share price. The shares opened for trading at $51.95 and hit $56.8 on the upside , eventually ending the session at $55.73, with a gain of 13.87% or 6.79 points. The heightened volatility saw the trading volume jump to 2,11,26,825 shares. The 52-week high of the share price is $56.8 and the company has a market cap of $2,669 M . The 52-week low of the share price is at $8.

Sarepta Therapeutics Inc Money Flow Index Chart

Company has been under the radar of several Street Analysts.Sarepta Therapeutics Inc is Reiterated by Needham to Buy and the brokerage firm has raised the Price Target to $ 81 from a previous price target of $47 .The Rating was issued on Sep 20, 2016.Sarepta Therapeutics Inc is Reiterated by Robert W. Baird to Outperform and the brokerage firm has raised the Price Target to $ 102 from a previous price target of $23 .The Rating was issued on Sep 19, 2016.Sarepta Therapeutics Inc is Upgraded by RBC Capital Mkts to Outperform and the brokerage firm has raised the Price Target to $ 83 from a previous price target of $5 .Earlier the firm had a rating of Sector Perform on the company shares. The Rating was issued on Sep 19, 2016.Sarepta Therapeutics Inc is Upgraded by Jefferies to Hold. Earlier the firm had a rating of Underperform on the company shares. The Rating was issued on Sep 19, 2016.Sarepta Therapeutics Inc is Reiterated by Needham to Buy and the brokerage firm has raised the Price Target to $ 26 from a previous price target of $20 .The Rating was issued on Jul 22, 2016.

Sarepta Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates including its lead DMD product candidate eteplirsen which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious rare and other human diseases.

Leave a Reply

Sarepta Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Sarepta Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.